Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates sustained efficacy and manageable toxicity of imatinib in chronic myeloid leukemia over 11 years, confirming its durability as standard long-term therapy.
Key Points
- To assess the long-term efficacy, cumulative toxicity, and safety profile of imatinib therapy in chronic myeloid leukemia over extended follow-up.
- Follow-up evaluation of patients enrolled in the IRIS randomized clinical trials (ClinicalTrials.gov numbers NCT00006343 and NCT00333840) receiving imatinib.
- Patients were evaluated over a follow-up period of almost 11 years for sustained treatment response, late toxicities, and cumulative adverse effects.
- Therapeutic efficacy of imatinib persisted over nearly 11 years of continuous follow-up.
- Long-term administration of imatinib was not associated with unacceptable cumulative toxic effects or late-emerging adverse events.
Cite This Study
Hochhaus et al. (2017) studied this question.